We recently modelled population testing for multiple BC and OC gene mutations (BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2) compared to the traditional clinical-criteria/FH-based approach [16]. The gene discussed is PALB2; the disease is breast cancer.